These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35315249)

  • 1. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
    Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron K; Benseler S; Berard RA; Broderick L; Dedeoglu F; Diebold M; Durrant K; Ferguson P; Foell D; Hausmann JS; Jones OY; Kastner D; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman HM; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
    Arthritis Rheumatol; 2022 Jul; 74(7):1102-1121. PubMed ID: 35621220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
    Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron KS; Benseler S; Berard R; Broderick L; Dedeoglu F; Diebold M; Durrant KL; Ferguson P; Foell D; Hausmann J; Jones OY; Kastner DL; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman H; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
    Ann Rheum Dis; 2022 Jul; 81(7):907-921. PubMed ID: 35623638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
    Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
    Front Immunol; 2022; 13():825367. PubMed ID: 35418997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics of 25 patients with type Ⅰ interferonopathies].
    Wang W; Wang W; Zou LP; He TY; Ma MS; Li WD; Yu ZX; Yang J; Song HM
    Zhonghua Er Ke Za Zhi; 2021 Dec; 59(12):1043-1047. PubMed ID: 34856663
    [No Abstract]   [Full Text] [Related]  

  • 12. Type I interferonopathies in pediatric rheumatology.
    Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING palmitoylation as a therapeutic target.
    Hansen AL; Mukai K; Schopfer FJ; Taguchi T; Holm CK
    Cell Mol Immunol; 2019 Mar; 16(3):236-241. PubMed ID: 30796349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
    Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).
    Papendorf JJ; Ebstein F; Alehashemi S; Piotto DGP; Kozlova A; Terreri MT; Shcherbina A; Rastegar A; Rodrigues M; Pereira R; Park S; Lin B; Uss K; Möller S; da Silva Pina AF; Sztajnbok F; Torreggiani S; Niemela J; Stoddard J; Rosenzweig SD; Oler AJ; McNinch C; de Guzman MM; Fonseca A; Micheloni N; Fraga MM; Perazzio SF; Goldbach-Mansky R; de Jesus AA; Krüger E
    Front Immunol; 2023; 14():1190104. PubMed ID: 37600812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
    de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
    J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.
    McDermott A; Jacks J; Kessler M; Emanuel PD; Gao L
    Int J Dermatol; 2015 Feb; 54(2):121-9. PubMed ID: 25521013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.